BASIS OF FINANCIAL STATEMENT PRESENTATION (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Accounts, Notes, Loans and Financing Receivable [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification		$ 5.9		$ 9.8
Weighted Average Number Diluted Shares Outstanding Adjustment		0.2		0.2
Ownership percentage below which investments are generally accounted for on the cost method (in thousandths)	20.00%
Prior Period Reclassification Adjustment		$ 1.4		$ 3.8
LabCorp Diagnostics [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percent of Revenue Contributed	72.00%		71.70%
Covance Drug Development [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percent of Revenue Contributed	28.00%			28.30%